Small cell lung cancer (SCLC) accounts for 13-15% of all new lung cancer cases and represents the sixth most commonly diagnosed cancer in the US. However, it is an understudied cancer for which no molecularly targeted approaches have shown benefit. Using high-throughput techniques such as proteomics and metabolomics we can provide a more global, unbiased characterization to the inner workings of this disease. Integrating disparate data is a challenge in data analysis and bioinformatics, but this challenge is worth confronting due to the potential for combined proteomics / metabolomics analyses to better interrogate and capture the global landscape of active pathways and networks in SCLC than either technology alone.
Integrating proteomics and metabolomics characterizes active pathways and potential drug targets in small cell lung cancer [Abstract 3752]
Stewart, D., Li, JN., Fisher, KJ., Dhungana, S., Sumner, S., Gardner, E., Poirier, J., Rudin, CM., Welsh, EA., Eschrich, S., Chen, A., & Haura, EB. (2015). Integrating proteomics and metabolomics characterizes active pathways and potential drug targets in small cell lung cancer [Abstract 3752]. Cancer Research, 75(15 Suppl), A3752. https://doi.org/10.1158/1538-7445.am2015-3752